Resumo
Doenças cardiovasculares (DCV) continuam a ser a principal causa de mortalidade em todo o mundo. Despite major advancements in pharmacological and surgical treatments, myocardial tissue regeneration remains a significant challenge. Stem cell-based therapy, particularly intravenous (4) stem cell administration, has emerged as a promising modality to repair, regenerate, and restore cardiac function. This article explores the pathophysiology of various cardiac diseases, the biochemical and molecular mechanisms underlying stem cell therapy, and evaluates the efficacy of IV stem cell injections in treating these conditions. Emphasis is placed on ischemic heart disease, infarto do miocárdio, e insuficiência cardíaca, which represent the most extensively studied cardiovascular indications for stem cell treatment.
Introdução
The heart, once thought to be a post-mitotic organ with limited regenerative capacity, agora é entendido como possuindo algum grau de plasticidade. Apesar disso, em caso de lesão significativa, como infarto do miocárdio, os mecanismos de reparação endógenos são insuficientes. As terapias tradicionais podem controlar os sintomas e prolongar a vida, mas não conseguem regenerar o miocárdio necrótico. A terapia com células-tronco busca superar essa limitação. Várias vias de administração foram exploradas, sendo a injeção intravenosa uma das opções menos invasivas e mais viáveis. Esta revisão fornece uma análise abrangente de como as células-tronco funcionam em nível bioquímico e molecular para combater a patologia cardíaca e restaurar a função.
Fisiopatologia das Doenças Cardiovasculares
1. Doença cardíaca isquêmica e infarto do miocárdio
A doença cardíaca isquêmica resulta de um desequilíbrio entre a oferta e a demanda de oxigênio do miocárdio, often due to atherosclerotic coronary artery disease. Atherosclerosis leads to plaque formation and narrowing of coronary vessels. When a plaque ruptures, it can occlude the vessel, causing myocardial infarction (MI).
Biochemical Pathways:
- Ischemia-induced oxidative stress leads to excessive production of reactive oxygen species (ROS).
- Calcium overload due to mitochondrial dysfunction.
- Activation of apoptotic and necrotic pathways through p53, Bax, and caspase cascades.
- Inflammatory signaling via NF-κB, TNF-α, IL-1β, and IL-6.
2. Insuficiência Cardíaca Crônica
Insuficiência cardíaca (AF) is characterized by the heart’s inability to pump sufficient blood to meet the body’s needs. It typically follows an MI or chronic hypertension.
Biochemical Pathways:
- Neurohormonal activation, especially of the renin-angiotensin-aldosterone system (RAAS).
- Elevated natriuretic peptides (BNP, ANP) as compensatory mechanisms.
- Increased oxidative stress and mitochondrial dysfunction.
- Matrix metalloproteinases (MMPs) activation leading to extracellular matrix remodeling.
Células-tronco: Types and Mechanisms
Types of Stem Cells Used in Cardiology
- Células-tronco mesenquimais (MSC): Derivado da medula óssea, tecido adiposo, cordão umbilical. Known for immunomodulatory and paracrine effects.
- Células-tronco pluripotentes induzidas (iPSCs): Generated from adult somatic cells, reprogrammed to a pluripotent state.
- Células-tronco cardíacas (CSCs): Native to the myocardium, capable of differentiating into cardiac lineages.
- Células Progenitoras Endoteliais (EPCs): Contribute to angiogenesis and endothelial repair.
Mecanismos de Ação
- Sinalização parácrina: Release of growth factors (VEGF, IGF-1, HGF, SDF-1) that stimulate repair.
- Imunomodulação: MSCs suppress pro-inflammatory cytokines and promote regulatory T cell activity.
- Angiogênese: Promoting neovascularization to improve perfusion.
- Anti-apoptotic effects: Reduction in caspase activity and improved mitochondrial integrity.
- Differentiation: Limited evidence suggests potential for integration into myocardium and differentiation into cardiomyocytes.
Intravenous Delivery of Stem Cells
Vantagens
- Minimamente invasivo.
- Easier to perform repeatedly.
- Potential for systemic effects, including remote ischemic zones.
Disadvantages
- Pulmonary first-pass effect: A significant proportion of cells are trapped in the lungs.
- Homogeneity and cell survival issues: Reduced targeting to myocardium.
Strategies to Enhance IV Efficacy
- Preconditioning of cells with hypoxia or pharmacologic agents.
- Genetic modification to overexpress chemokine receptors like CXCR4 to enhance homing.
- Use of nanoparticles or scaffolds to increase retention and viability.
Clinical Applications and Evidence
1. Myocardial Infarction
Numerous clinical trials (POR EXEMPLO, BOOST, REPAIR-AMI) have demonstrated improved left ventricular ejection fraction (LVEF) and reduced infarct size after IV administration of bone marrow-derived stem cells.
2. Chronic Ischemic Heart Disease
Studies using MSCs have shown improvements in exercise tolerance and angina frequency, attributed to enhanced myocardial perfusion via angiogenesis.
3. Insuficiência Cardíaca Congestiva
MSC therapy has shown promise in reducing hospitalizations, improving NYHA functional class, and enhancing quality of life. Paracrine effects are believed to reduce fibrosis and promote cardiomyocyte survival.
Biochemical and Molecular Insights
Stem cell therapy affects several molecular pathways:
- PI3K/Akt and ERK1/2 pathways: Promote cell survival and proliferation.
- Eixo SDF-1/CXCR4: Critical for stem cell homing.
- HIF-1α stabilization: Enhances angiogenesis in hypoxic tissue.
- TGF-β modulation: Reduces pathological remodeling.
- miRNA expression: miR-21, miR-126, and others modulated by stem cell therapy contribute to anti-apoptotic and pro-angiogenic effects.
Interessado em saber se os programas clínicos atuais, desenvolvimentos de pesquisa, ou abordagens terapêuticas emergentes podem ser relevantes para a sua situação?
Apenas informações educacionais e de pesquisa. As decisões médicas individuais devem ser tomadas em consulta com profissionais de saúde qualificados.
